BioLife Solutions (BLFS) 10-K 15 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Mar. 08, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Entity Central Index Key	0000834365
Trading Symbol	blfs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		18,651,678
Entity Public Float			$ 115
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 30,657	$ 6,663
Accounts receivable, trade, net of allowance for doubtful accounts of $0 and $6 at December 31, 2018 and 2017, respectively	3,045	1,021
Inventories	3,509	1,847
Prepaid expenses and other current assets	353	400
Total current assets	37,564	9,931
Property and equipment
Leasehold improvements	1,284	1,284
Furniture and computer equipment	706	682
Manufacturing and other equipment	1,657	1,149
Subtotal	3,647	3,115
Less: Accumulated depreciation	(2,328)	(2,009)
Net property and equipment	1,319	1,106
Investment in SAVSU	6,548	1,070
Long-term deposits	36	36
Total assets	45,467	12,143
Current liabilities
Accounts payable	720	691
Accrued expenses and other current liabilities	91	201
Accrued compensation	998	491
Deferred rent, current portion	130	130
Total current liabilities	1,939	1,513
Deferred rent, long-term	349	492
Other long-term liabilities	31	46
Total liabilities	2,319	2,051
Commitments and Contingencies (Note 8)
Shareholders’ equity
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 and 4,250 shares issued and outstanding at December 31, 2018 and 2017, respectively
Common stock, $0.001 par value; 150,000,000 shares authorized, 18,547,406 and 14,021,422 shares issued and outstanding at December 31, 2018 and 2017, respectively	19	14
Additional paid-in capital	114,160	84,036
Accumulated deficit	(71,031)	(73,958)
Total shareholders’ equity	43,148	10,092
Total liabilities and shareholders’ equity	$ 45,467	$ 12,143

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 0	$ 6
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	18,547,406	14,021,422
Common stock, outstanding (in shares)	18,547,406	14,021,422
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)		$ 1,000
Preferred stock, designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	4,250
Preferred stock, outstanding (in shares)	0	4,250

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Product sales	$ 19,742	$ 11,022
Cost of product sales	6,217	4,276
Gross profit	13,525	6,746
Operating expenses
Research and development	1,298	1,193
Sales and marketing	2,615	2,086
General and administrative	5,950	4,523
Total operating expenses	9,863	7,802
Operating income (loss)	3,662	(1,056)
Other income (expenses)
Interest income	281	1
Interest expense	(5)	(190)
Loss from equity-method investment in SAVSU	(672)	(1,005)
Financing costs and write off of deferred financing costs		(109)
Amortization of debt discount		(156)
Total other income (expenses)	(396)	(1,459)
Net income (loss) before provision for income taxes	3,266	(2,515)
Income taxes
Net income (loss)	3,266	(2,515)
Less: Preferred stock dividends and accumulated deficit impact of preferred stock redemption	(339)	(213)
Net income (loss) attributable to common stockholders	$ 2,927	$ (2,728)
Basic net income (loss) per common share (in dollars per share)	$ 0.18	$ (0.21)
Diluted net income (loss) per common share (in dollars per share)	$ 0.14	$ (0.21)
Weighted average shares outstanding used to compute basic earnings per share (in shares)	16,256,465	13,263,881
Weighted average shares outstanding used to compute diluted earnings per share (in shares)	21,627,278	13,263,881

Statements of Shareholders' Equ

Statements of Shareholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		12,863,824
Balance at Dec. 31, 2016		$ 13	$ 74,356	$ (71,202)	$ 3,167
Cumulative-effect adjustment resulting from adoption of ASU 2016-09 at Dec. 31, 2016			28	(28)
Vesting of JV related stock-based compensation			22		22
Series A preferred stock issued on conversion of related party note and accrued interest on June 30, 2017, net of stock issuance costs of $9 (in shares)	4,250
Series A preferred stock issued on conversion of related party note and accrued interest on June 30, 2017, net of stock issuance costs of $9			4,241		4,241
Stock based compensation			1,270		1,270
Stock option/warrant exercises (in shares)		1,045,719
Stock option/warrant exercises		$ 1	3,977		3,978
Stock issued – on vested RSUs (in shares)		51,563
Stock issued for services (in shares)		60,316
Stock issued for services			142		142
Preferred stock dividends				(213)	(213)
Net income (loss)				(2,515)	(2,515)
Balance (in shares) at Dec. 31, 2017	4,250	14,021,422
Balance at Dec. 31, 2017		$ 14	84,036	(73,958)	10,092
Stock based compensation			1,519		1,519
Stock option/warrant exercises (in shares)		2,974,827
Stock option/warrant exercises		$ 3	12,897		12,900
Stock issued – on vested RSUs (in shares)		116,647
Stock issued for services (in shares)		5,939
Stock issued for services			36		36
Preferred stock dividends				(330)	(330)
Net income (loss)				3,266	3,266
Series A preferred stock redemption (in shares)	(4,250)
Series A preferred stock redemption			(4,241)	(9)	(4,250)
Stock issued for private equity transaction – Casdin Capital, net of legal fees of $85 (in shares)		1,428,571
Stock issued for private equity transaction – Casdin Capital, net of legal fees of $85		$ 2	19,913		19,915
Balance (in shares) at Dec. 31, 2018		18,547,406
Balance at Dec. 31, 2018		$ 19	$ 114,160	$ (71,031)	$ 43,148

Statements of Shareholders' E_2

Statements of Shareholders' Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Additional Paid-in Capital [Member]
Issuance fees	$ 85	$ 9

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net income (loss)	$ 3,266,000	$ (2,515,000)
Adjustments to reconcile net income (loss) to net cash provided by operating activities
Depreciation	338,000	339,000
Stock-based compensation expense	1,519,000	1,270,000
Stock issued for services		107,000
Write off of deferred financing costs		68,000
Amortization of debt discount		156,000
Loss from equity-method investment in SAVSU	672,000	1,005,000
Amortization of deferred rent related to lease incentives	(127,000)	(127,000)
Change in operating assets and liabilities
Accounts receivable, trade	(2,024,000)	172,000
Inventories	(1,662,000)	(89,000)
Prepaid expenses and other current assets	(104,000)	(181,000)
Accounts payable	(11,000)	21,000
Accrued compensation and other current liabilities	497,000	292,000
Accrued interest		152,000
Deferred rent	(16,000)	(65,000)
Net cash provided by operating activities	2,348,000	605,000
Cash flows from investing activities
Investment in SAVSU	(6,000,000)
Purchase of property and equipment	(500,000)	(144,000)
Net cash used in investing activities	(6,500,000)	(144,000)
Cash flows from financing activities
Proceeds from private equity transaction	20,000,000
Proceeds from note payable to related party		1,000,000
Proceeds from exercise of common stock options and warrants	12,900,000	3,978,000
Payments on equipment loan	(12,000)	(13,000)
Payments on capital lease obligation	(13,000)	(11,000)
Payments for redemption of preferred stock	(4,250,000)
Payments related to stock issuance	(43,000)	(9,000)
Payments of preferred stock dividends	(436,000)	(106,000)
Deferred costs paid related to potential stock issuance		(43,000)
Net cash provided by financing activities	28,146,000	4,796,000
Net increase in cash and cash equivalents	23,994,000	5,257,000
Cash and cash equivalents - beginning of year	6,663,000	1,406,000
Cash and cash equivalents - end of year	30,657,000	6,663,000
Non-cash investing and financing activities
Series A preferred stock dividends accrued not yet paid		106,000
Stock issued for services in prior period included in liabilities at prior year-end	36,000	36,000
Receivables converted to equity investment in SAVSU	150,000
Preferred stock issued to convert related party note payable and accrued interest		4,250,000
Capital lease obligations incurred for purchase of equipment		52,000
Purchase of equipment with debt	18,000	39,000
Legal fees for private equity transaction not yet paid	44,000
Purchase of property and equipment not yet paid	$ 54,000	$ 22,000

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and Significant Accounting Policies Business BioLife Solutions, Inc. (“BioLife,” “us,” “we,” “our,” or the “Company”) is a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Our proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. Our biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. Additionally, for our direct, distributor, and contract customers, we perform custom formulation, fill, and finish services. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Earnings per share Basic earnings per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the year ended December 31, 2018, December 31, 2017, 3.4 6.7 238,000 The following table shows the calculation of basic and diluted earnings per share: Year Ended December 31, (In thousands , except share and earnings per share data ) 2018 2017 Numerator: Net income (loss) attributable to common stockholders $ 2,927 $ (2,728 ) Denominator: Weighted average basic shares outstanding 16,256,465 13,263,881 Effect of dilutive securities 5,370,813 — Weighted average diluted shares 21,627,278 13,263,881 Basic earnings per share $ 0.18 $ (0.21 ) Diluted earnings per share $ 0.14 $ (0.21 ) Cash and cash equivalents Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not We paid $5,000 $38,000 December 31, 2018 2017, Equity Method Investments We account for our ownership in SAVSU Technologies, Inc. (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, January 22, 2018, 35%, December 31, 2016. 35% December 31, 2017. $6 44.4% December 31, 2018. 18 56% not 1,000,000 $23 As of December 31, 2018, $5.8 $11.0 $0.5 December 31, 2017, $0.6 $5.5 $0.2 December 31 2018 2017, $1.9 $2.2 December 31, 2018, Inventories Inventories represent biopreservation solutions, raw materials used to make biopreservation solutions and are stated at the lower of cost or net realizable value. Cost is determined using the first first Accounts receivable Accounts receivable are stated at principal amount, do not ninety Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Deferred rent For our operating leases, we recognize rent expense on a straight-line basis over the terms of the leases and, accordingly, we record the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Landlord-funded leasehold improvements, to the extent the improvements are not Revenue recognition On January 1, 2018, No. 2014 09, 606 January 1, 2018. January 1, 2018 not 605, not no To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, five five not one We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not not December 31, 2015 2018. Advertising Advertising costs are expensed as incurred and totaled $30,000 $39,000 December 31, 2018 2017, Operating segments As described above, our activities are directed in the life sciences field of biopreservation products and services. As of December 31, 2018, 2017 Concentrations of credit risk and business risk In the years 2018 2017, 29% two 12% one 13% 10% December 31, 2018. 11% 16% December 31, 2017. December 31, 2018, three 71% December 31, 2017, two 41% 2018 2017, 88% 77%, Research and development Research and development costs are expensed as incurred. Stock Based Compensation We use the Black-Scholes option pricing model as our method of valuation for stock option awards. Restricted stock unit grants are valued at the fair value of our common stock on the date of grant. Share-based compensation expense is based on the value of the portion of the stock-based award that will vest during the period, adjusted for forfeitures. Our determination of the fair value of stock option awards on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not The fair value of options at the date of grant is determined under the Black-Scholes option pricing model. We did not December 31, 2018. December 31, 2017, Assumptions 2017 Risk-free rate 2.12 % Annual rate of dividends –– Historical volatility 74 % Expected life (in years) 5.7 The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. We do not may not Management adopted Financial Accounting Standards Board (“FASB”) Accounting Standard Update No. 2016 09 January 1, 2017. 2016 09 not $28,000 Recent accounting pronouncements In August 2016, No. 2016 15, 230 2016 15 January 1, 2018, no In February 2016, No. 2016 02, 842 2016 02 2016 02. December 15, 2018. 842 January 1, 2019 not December 31, 2018, $1.8 $1.9 In January 2016, No. 2016 01, 825 2016 01 January 1, 2018, no With the exception of the new standards discussed above, there have been no not

Note 2 - Fair Value Measurement

Note 2 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2 . Fair Value Measurement In accordance with FASB ASC Topic 820, 820” 820 820 three Level 1 Level 2 1 not Level 3 As of December 31, 2018 2017, not The following tables set forth the Company’s assets measured at fair value on a recurring basis as of December 31, 2018 December 31, 2017, three (In thousands) As of December 31, 201 8 Level 1 Level 2 Total Total Cash and cash equivalents $ 30,657 $ — $ 30,657 As of December 31, 201 7 Level 1 Level 2 Total Total Cash and cash equivalents $ 6,663 $ — $ 6,663 The fair values of bank deposits and money market funds classified as Level 1 no 2 3 not 1 2 December 31, 2018 2017.

Note 3 - Inventories

Note 3 - Inventories	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	3 . Inventories Inventories consist of the following at December 31, 2018 2017: (In thousands) 201 8 201 7 Raw materials $ 1,453 $ 583 Work in progress 652 454 Finished goods 1,404 810 Total $ 3,509 $ 1,847

Note 4 - Deferred Rent

Note 4 - Deferred Rent	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Deferred Rent [Text Block]	4 . Deferred Rent Deferred rent consists of the following at December 31, 2018 2017: (In thousands) 201 8 201 7 Landlord-funded leasehold improvements $ 1,125 $ 1,125 Less accumulated amortization (757 ) (630 ) Total (current portion $130 at December 31, 2018 and 2017) 368 495 Straight line rent adjustment 111 127 Total deferred rent $ 479 $ 622 During each of the years ended December 31, 2018 2017, $127,000 In addition, during the years ended December 31, 2018 2017, $16,000 $65,000,

Note 5 - Income Taxes

Note 5 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5 . Income Taxes Income tax benefit reconciled to tax calculated at statutory rates is as follows: (In thousands) 201 8 201 7 Federal tax expense (benefit) on net income/loss at statutory rate $ 686 $ (855 ) Change in valuation allowance (412 ) (3,419 ) Basis difference related to investment in SAVSU –– (110 ) Return to provision 52 (1,038 ) Federal rate change true-up –– 5,421 Stock compensation (748 ) –– Book loss in SAVSU 141 –– 162(m) limitation on executive compensation deductibility 296 –– Other (15 ) 1 Benefit (expense) for income taxes, net $ –– $ –– At December 31, 2018 2017, (In thousands) 201 8 201 7 Deferred tax assets (liabilities) Net operating loss carryforwards $ 7,381 $ 8,162 Accrued compensation 181 32 Depreciation (24 ) 43 Section 263a inventory adjustment 42 29 Stock-based compensation 664 688 Deferred rent 101 –– Outside basis difference in SAVSU –– (225 ) Other –– 28 Total 8,345 8,757 Less: Valuation allowance (8,345 ) (8,757 ) Net deferred tax asset $ –– $ –– On December 22, 2017, “H.R.1”, H.R.1 21% 35%, January 1, 2018. December 31, 2017. $5.4 December 31, 2017. 2018 $2.3 $2.3 The Company has the following net operating loss tax carryforwards available at December 31, 2018: (In thousands) Year of Expiration Net Operating 2019 $ 259 2020 2,849 2021 4,168 2023 1,217 2024 646 2025 589 2026 873 2027 2,607 2028 2,512 2029 2,196 2030 1,232 2031 1,028 2032 437 2033 37 2034 6,409 2035 3,093 2036 4,995 Total $ 35,147 Based on historical losses and potential future changes in the ownership of the Company, the utilization of such loss and tax credit carryforwards could be substantially limited. We have recorded a full valuation allowance against our deferred tax assets. As we trend towards positive net income, we will continue to assess our valuation allowance. Based on all available evidence, we determined that we have not December 31, 2018. may

Note 6 - Warrants

Note 6 - Warrants	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Warrants [Text Block]	6 . Warrants The following table summarizes warrant activity for the years ended December 31, 2018 2017: Year Ended Year Ended (In thousands, except exercise price) December 31, 2018 December 31, 201 7 Wtd. Avg. Wtd. Avg. Exercise Exercise Shares Price Shares Price Outstanding at beginning of year 6,689 $ 4.50 7,603 $ 4.46 Exercised (2,609 ) 4.75 (914 ) 4.18 Outstanding and exercisable at end of year 4,080 $ 4.35 6,689 $ 4.50 The outstanding warrants have expiration dates between March 2021 May 2021.

Note 7 - Stock-based Compensati

Note 7 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7 . Stock-Based Compensation Stock Compensation Plans Our stock-based compensation programs are long-term retention programs that are intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. We have the following stock-based compensation plans and programs: During 2013, 2013 “2013 3.1 2013 May 2017, 4.1 December 31, 2018, 2.6 280,000 2013 The Company also issued, outside any approved compensation plans, non-incentive stock options. As of December 31, 2018, 425,000 Issuance of Shares When options and warrants are exercised, it is the Company’s policy to issue new shares. Stock Option Activity Service Vesting-Based Stock Options The following is a summary of service vesting-based stock option activity for 2018 2017, December 31, 2018 2017: Year Ended Year Ended December 31, 201 8 December 31, 201 7 Wtd. Avg. Wtd. Avg. Exercise Exercise Shares Price Shares Price Outstanding at beginning of year 2,390,012 $ 1.85 2,513,861 $ 1.78 Granted –– –– 155,000 2.93 Exercised (330,983 ) 1.36 (131,427 ) 1.17 Forfeited (15,627 ) 4.34 (52,932 ) 3.45 Expired - vested –– –– (94,490 ) 1.78 Outstanding at end of year 2,043,402 $ 1.91 2,390,012 $ 1.85 Stock options exercisable at year end 1,661,999 $ 1.87 1,583,585 $ 1.72 We recognized stock compensation expense of $597,000 $612,000 December 31, 2018 2017, none $1.91 December 31, 2018 2017, During the year ended December 31, 2018, 330,983 $3.8 December 31, 2017, 131,427 $91,817 As of December 31, 2018, $20.7 $16.9 2018 December 31, 2018. The following table summarizes information about service vesting-based stock options outstanding at December 31, 2018: Range of Exercise Prices Number Outstanding at December 31, 201 8 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 0.49 - 1.00 3,571 2.91 $ .49 $ 1.01 - 1.50 412,073 1.91 $ 1.24 $ 1.51 - 2.50 1,549,367 6.52 $ 1.94 $ 2.51 - 8.60 78,391 6.69 $ 4.99 2,043,402 5.59 $ 1.91 The weighted average remaining contractual life of exercisable service vesting-based options at December 31, 2018, 5.4 December 31, 2018 $531,000 1.5 Performance-based Stock Options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 1,000,000 may $1.64, 2017 50% 2017, 50% one not no February 27, 2018, 2017 999,997 50% March 8, 2018 50% March 8, 2019. The following is a summary of performance-based stock option activity under our stock option plans for 2018 2017, December 31, 2018 2017: Year Ended Year Ended December 31, 2018 December 31, 2017 Wtd. Avg. Wtd. Avg. Exercise Exercise Shares Price Shares Price Outstanding at beginning of year 999,997 $ 1.64 999,997 $ 1.64 Granted –– –– –– –– Exercised (35,000 ) 1.64 –– –– Outstanding at end of year 964,997 $ 1.64 999,997 $ 1.64 Stock options exercisable at year end 465,001 $ 1.64 –– $ –– We recognized stock compensation expense of $509,000 December 31, 2018 2017. December 31, 2018, 35,000 $285,000 December 31, 2018, $10.0 $4.8 December 31, 2018, 3.0 2017 December 31, 2018. Restricted Stock The following is a summary of unvested restricted stock activity for 2018 2017, December 31, 2018 2017: Year Ended Year Ended December 31, 201 8 December 31, 201 7 Wtd. Avg. Wtd. Avg. Grant Date Grant Date Shares Fair Value Shares Fair Value Outstanding at beginning of year 237,926 $ 1.79 98,439 $ 1.90 Granted 181,268 7.02 207,350 1.76 Vested (116,647 ) 1.81 (51,563 ) 1.90 Forfeited (22,628 ) 3.95 (16,300 ) 1.76 Non-vested at end of year 279,919 $ 5.00 237,926 $ 1.79 The aggregate fair value of the awards granted during the years ended December 31, 2018 2017 $1.3 $365,000, December 31, 2018 2017 $1.1 $154,000, We recognized stock compensation expense of $413,000 $149,000 December 31, 2018 2017, December 31, 2018, $1.1 3.0 We recorded total stock compensation expense for the years ended December 31, 2018 2017, Year Ended December 31, (In thousands) 2018 201 7 Research and development costs $ 260 $ 237 Sales and marketing costs 269 231 General and administrative costs 809 638 Cost of product sales 181 164 Total $ 1,519 $ 1,270

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8 . Commitments and Contingencies Leases We lease approximately 32,000 July 31, 2021 two five first August 1, 2021, second first $59,000 December 31, 2018, August October The following is a schedule of future minimum lease payments required under the facility leases as of December 31, 2018: Year Ending (In thousands) December 31 2019 $ 748 2020 764 2021 452 Total $ 1,964 Rental expense for this facility lease for the years ended December 31, 2018 2017 $809,000 $755,000, Employment agreements We have employment agreements with our Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice President of Operations, Vice President of Marketing, and Vice President of Sales. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none

Note 9 - Preferred Stock

Note 9 - Preferred Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9 . Preferred Stock On June 30, 2017, $4.25 June 1, 2017, 4,250 No no December 31, 2017, 4,250 $1,000 10%. May 17, 2018 25%, 1,063 $1,063,000. November 27, 2018 3,187 $3,187,000. no no December 31, 2018.

Note 10 - Revenue

Note 10 - Revenue	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	10. Revenue The following table disaggregates revenue by market segment and distributors: Year Ended December 31, (In thousands) 2018 2017 Regenerative Medicine $ 11,029 $ 5,307 Distributors 6,418 3,232 Drug discovery 1,199 1,318 BioBanking 1,096 1,165 Total $ 19,742 $ 11,022

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	1 1 . Subsequent Event Astero Acquisition On March 13, 2019, one hundred 100% In connection with the Acquisition, the Company will pay to the Sellers (i) a base payment in the amount of $12,500,000, x $8,000,000 $4,500,000 one 2019, 2020 2021 $3,500,000, $5,000,000 2021 three 2019 2021 The obligations of the parties to consummate the Acquisition is subject to the following closing conditions: (i) the satisfaction of the representations and warranties in the Purchase Agreement, by each party, (ii) performance in all material respects each parties respective obligations in all materials respects of the Purchase Agreement by each party, (iii) delivery of the closing deliverables by each party and (iv) for only Astero and the Sellers, proof that no Pursuant to the terms of the Purchase Agreement, at or prior to the Closing, the Company, the Seller Representative, and Continental Stock Transfer & Trust Company (the “Escrow Agent”), shall enter into an escrow agreement (the “Escrow Agreement”). At the Closing, the Company shall pay to the Escrow Agent by wire transfer in immediately available funds (i) $1,000,000 x $250,000 $750,000 18 $3,750,000 one

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Earnings per share Basic earnings per share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated using the weighted average number of common shares outstanding plus dilutive common stock equivalents outstanding as determined by the treasury method during the period. In periods when we have a net loss, common stock equivalents are excluded from our calculation of earnings per share as their inclusion would have an antidilutive effect. For the year ended December 31, 2018, December 31, 2017, 3.4 6.7 238,000 The following table shows the calculation of basic and diluted earnings per share: Year Ended December 31, (In thousands , except share and earnings per share data ) 2018 2017 Numerator: Net income (loss) attributable to common stockholders $ 2,927 $ (2,728 ) Denominator: Weighted average basic shares outstanding 16,256,465 13,263,881 Effect of dilutive securities 5,370,813 — Weighted average diluted shares 21,627,278 13,263,881 Basic earnings per share $ 0.18 $ (0.21 ) Diluted earnings per share $ 0.14 $ (0.21 )
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not We paid $5,000 $38,000 December 31, 2018 2017,
Equity Method Investments [Policy Text Block]	Equity Method Investments We account for our ownership in SAVSU Technologies, Inc. (“SAVSU”) using the equity method of accounting. This method states that if the investment provides us the ability to exercise significant influence, but not 20% 50%, January 22, 2018, 35%, December 31, 2016. 35% December 31, 2017. $6 44.4% December 31, 2018. 18 56% not 1,000,000 $23 As of December 31, 2018, $5.8 $11.0 $0.5 December 31, 2017, $0.6 $5.5 $0.2 December 31 2018 2017, $1.9 $2.2 December 31, 2018,
Inventory, Policy [Policy Text Block]	Inventories Inventories represent biopreservation solutions, raw materials used to make biopreservation solutions and are stated at the lower of cost or net realizable value. Cost is determined using the first first
Receivables, Policy [Policy Text Block]	Accounts receivable Accounts receivable are stated at principal amount, do not ninety
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten
Lessee, Leases [Policy Text Block]	Deferred rent For our operating leases, we recognize rent expense on a straight-line basis over the terms of the leases and, accordingly, we record the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. Landlord-funded leasehold improvements, to the extent the improvements are not
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition On January 1, 2018, No. 2014 09, 606 January 1, 2018. January 1, 2018 not 605, not no To determine revenue recognition for contractual arrangements that we determine are within the scope of Topic 606, five five not one We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are presented as accounts receivable on our balance sheet. Accounts receivable consist of short-term amounts due from our customers (generally 30 90
Income Tax, Policy [Policy Text Block]	Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not not December 31, 2015 2018.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are expensed as incurred and totaled $30,000 $39,000 December 31, 2018 2017,
Segment Reporting, Policy [Policy Text Block]	Operating segments As described above, our activities are directed in the life sciences field of biopreservation products and services. As of December 31, 2018, 2017
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk and business risk In the years 2018 2017, 29% two 12% one 13% 10% December 31, 2018. 11% 16% December 31, 2017. December 31, 2018, three 71% December 31, 2017, two 41% 2018 2017, 88% 77%,
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation We use the Black-Scholes option pricing model as our method of valuation for stock option awards. Restricted stock unit grants are valued at the fair value of our common stock on the date of grant. Share-based compensation expense is based on the value of the portion of the stock-based award that will vest during the period, adjusted for forfeitures. Our determination of the fair value of stock option awards on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not The fair value of options at the date of grant is determined under the Black-Scholes option pricing model. We did not December 31, 2018. December 31, 2017, Assumptions 2017 Risk-free rate 2.12 % Annual rate of dividends –– Historical volatility 74 % Expected life (in years) 5.7 The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. We do not may not Management adopted Financial Accounting Standards Board (“FASB”) Accounting Standard Update No. 2016 09 January 1, 2017. 2016 09 not $28,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In August 2016, No. 2016 15, 230 2016 15 January 1, 2018, no In February 2016, No. 2016 02, 842 2016 02 2016 02. December 15, 2018. 842 January 1, 2019 not December 31, 2018, $1.8 $1.9 In January 2016, No. 2016 01, 825 2016 01 January 1, 2018, no With the exception of the new standards discussed above, there have been no not

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, (In thousands , except share and earnings per share data ) 2018 2017 Numerator: Net income (loss) attributable to common stockholders $ 2,927 $ (2,728 ) Denominator: Weighted average basic shares outstanding 16,256,465 13,263,881 Effect of dilutive securities 5,370,813 — Weighted average diluted shares 21,627,278 13,263,881 Basic earnings per share $ 0.18 $ (0.21 ) Diluted earnings per share $ 0.14 $ (0.21 )
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumptions 2017 Risk-free rate 2.12 % Annual rate of dividends –– Historical volatility 74 % Expected life (in years) 5.7

Note 2 - Fair Value Measureme_2

Note 2 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	As of December 31, 201 8 Level 1 Level 2 Total Total Cash and cash equivalents $ 30,657 $ — $ 30,657 As of December 31, 201 7 Level 1 Level 2 Total Total Cash and cash equivalents $ 6,663 $ — $ 6,663

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) 201 8 201 7 Raw materials $ 1,453 $ 583 Work in progress 652 454 Finished goods 1,404 810 Total $ 3,509 $ 1,847

Note 4 - Deferred Rent (Tables)

Note 4 - Deferred Rent (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Deferred Rent [Table Text Block]	(In thousands) 201 8 201 7 Landlord-funded leasehold improvements $ 1,125 $ 1,125 Less accumulated amortization (757 ) (630 ) Total (current portion $130 at December 31, 2018 and 2017) 368 495 Straight line rent adjustment 111 127 Total deferred rent $ 479 $ 622

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	(In thousands) 201 8 201 7 Federal tax expense (benefit) on net income/loss at statutory rate $ 686 $ (855 ) Change in valuation allowance (412 ) (3,419 ) Basis difference related to investment in SAVSU –– (110 ) Return to provision 52 (1,038 ) Federal rate change true-up –– 5,421 Stock compensation (748 ) –– Book loss in SAVSU 141 –– 162(m) limitation on executive compensation deductibility 296 –– Other (15 ) 1 Benefit (expense) for income taxes, net $ –– $ ––
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	(In thousands) 201 8 201 7 Deferred tax assets (liabilities) Net operating loss carryforwards $ 7,381 $ 8,162 Accrued compensation 181 32 Depreciation (24 ) 43 Section 263a inventory adjustment 42 29 Stock-based compensation 664 688 Deferred rent 101 –– Outside basis difference in SAVSU –– (225 ) Other –– 28 Total 8,345 8,757 Less: Valuation allowance (8,345 ) (8,757 ) Net deferred tax asset $ –– $ ––
Summary of Operating Loss Carryforwards [Table Text Block]	(In thousands) Year of Expiration Net Operating 2019 $ 259 2020 2,849 2021 4,168 2023 1,217 2024 646 2025 589 2026 873 2027 2,607 2028 2,512 2029 2,196 2030 1,232 2031 1,028 2032 437 2033 37 2034 6,409 2035 3,093 2036 4,995 Total $ 35,147

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Year Ended Year Ended (In thousands, except exercise price) December 31, 2018 December 31, 201 7 Wtd. Avg. Wtd. Avg. Exercise Exercise Shares Price Shares Price Outstanding at beginning of year 6,689 $ 4.50 7,603 $ 4.46 Exercised (2,609 ) 4.75 (914 ) 4.18 Outstanding and exercisable at end of year 4,080 $ 4.35 6,689 $ 4.50

Note 7 - Stock-based Compensa_2

Note 7 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Year Ended Year Ended December 31, 201 8 December 31, 201 7 Wtd. Avg. Wtd. Avg. Exercise Exercise Shares Price Shares Price Outstanding at beginning of year 2,390,012 $ 1.85 2,513,861 $ 1.78 Granted –– –– 155,000 2.93 Exercised (330,983 ) 1.36 (131,427 ) 1.17 Forfeited (15,627 ) 4.34 (52,932 ) 3.45 Expired - vested –– –– (94,490 ) 1.78 Outstanding at end of year 2,043,402 $ 1.91 2,390,012 $ 1.85 Stock options exercisable at year end 1,661,999 $ 1.87 1,583,585 $ 1.72 Year Ended Year Ended December 31, 2018 December 31, 2017 Wtd. Avg. Wtd. Avg. Exercise Exercise Shares Price Shares Price Outstanding at beginning of year 999,997 $ 1.64 999,997 $ 1.64 Granted –– –– –– –– Exercised (35,000 ) 1.64 –– –– Outstanding at end of year 964,997 $ 1.64 999,997 $ 1.64 Stock options exercisable at year end 465,001 $ 1.64 –– $ ––
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Range of Exercise Prices Number Outstanding at December 31, 201 8 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 0.49 - 1.00 3,571 2.91 $ .49 $ 1.01 - 1.50 412,073 1.91 $ 1.24 $ 1.51 - 2.50 1,549,367 6.52 $ 1.94 $ 2.51 - 8.60 78,391 6.69 $ 4.99 2,043,402 5.59 $ 1.91
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	Year Ended Year Ended December 31, 201 8 December 31, 201 7 Wtd. Avg. Wtd. Avg. Grant Date Grant Date Shares Fair Value Shares Fair Value Outstanding at beginning of year 237,926 $ 1.79 98,439 $ 1.90 Granted 181,268 7.02 207,350 1.76 Vested (116,647 ) 1.81 (51,563 ) 1.90 Forfeited (22,628 ) 3.95 (16,300 ) 1.76 Non-vested at end of year 279,919 $ 5.00 237,926 $ 1.79
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, (In thousands) 2018 201 7 Research and development costs $ 260 $ 237 Sales and marketing costs 269 231 General and administrative costs 809 638 Cost of product sales 181 164 Total $ 1,519 $ 1,270

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Year Ending (In thousands) December 31 2019 $ 748 2020 764 2021 452 Total $ 1,964

Note 10 - Revenue (Tables)

Note 10 - Revenue (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, (In thousands) 2018 2017 Regenerative Medicine $ 11,029 $ 5,307 Distributors 6,418 3,232 Drug discovery 1,199 1,318 BioBanking 1,096 1,165 Total $ 19,742 $ 11,022

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual)	Sep. 30, 2018USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Jan. 01, 2019USD ($)	Jan. 22, 2018	Jan. 01, 2017USD ($)	Dec. 31, 2016USD ($)
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total		$ 5,000	$ 38,000
Assets, Current, Total		37,564,000	9,931,000
Assets, Total		45,467,000	12,143,000
Liabilities, Total		2,319,000	2,051,000
Net Income (Loss) Attributable to Parent, Total		3,266,000	(2,515,000)
Liability for Uncertainty in Income Taxes, Current		0
Advertising Expense		$ 30,000	39,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares		0
Cumulative Effect of New Accounting Principle in Period of Adoption
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total		$ 0
Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member]
Operating Lease, Right-of-Use Asset				$ 1,800,000
Operating Lease, Liability, Total				$ 1,900,000
Retained Earnings [Member]
Net Income (Loss) Attributable to Parent, Total		3,266,000	(2,515,000)
Cumulative Effect of New Accounting Principle in Period of Adoption						$ 28,000	(28,000)
Additional Paid-in Capital [Member]
Net Income (Loss) Attributable to Parent, Total
Cumulative Effect of New Accounting Principle in Period of Adoption						$ 28,000	$ 28,000
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage		29.00%	12.00%
Number of Major Customers		2	1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | CANADA
Concentration Risk, Percentage		13.00%	11.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Foreign Countries [Member]
Concentration Risk, Percentage		10.00%	16.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage		71.00%	41.00%
Number of Major Customers		3	2
Product Concentration Risk [Member] | Sales Revenue, Net [Member] | CryoStor Products [Member]
Concentration Risk, Percentage		88.00%	77.00%
Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life		10 years
SAVSU [Member]
Assets, Current, Total		$ 5,800,000	$ 600,000
Assets, Total		11,000,000	5,500,000
Liabilities, Total		500,000	200,000
Net Income (Loss) Attributable to Parent, Total		$ 1,900,000	$ 2,200,000
SAVSU [Member]
Equity Method Investment, Ownership Percentage		44.40%	35.00%		35.00%
Payments to Acquire Equity Method Investments		$ 6,000,000
Purchase Option, Term	1 year 180 days
Purchase Option, Additional Ownership Percentage to be Acquired	56.00%
Purchase Option, Consideration Transferred, Equity Interests Issuable, Shares | shares	1,000,000
Purchase Option, Consideration Transferred, Equity Interests Issuable	$ 23,000,000
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			3,400,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			6,700,000
Unvested Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			238,000

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net income (loss) attributable to common stockholders	$ 2,927	$ (2,728)
Weighted average shares outstanding used to compute basic earnings per share (in shares)	16,256,465	13,263,881
Effect of dilutive securities (in shares)	5,370,813
Weighted average diluted shares (in shares)	21,627,278	13,263,881
Basic net income (loss) per common share (in dollars per share)	$ 0.18	$ (0.21)
Diluted net income (loss) per common share (in dollars per share)	$ 0.14	$ (0.21)

Note 1 - Organization and Sig_5

Note 1 - Organization and Significant Accounting Policies - Fair Value Assumptions (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2017
Risk-free rate	2.12%
Annual rate of dividends
Historical volatility	74.00%
Expected life (in years) (Year)	5 years 255 days

Note 2 - Fair Value Measureme_3

Note 2 - Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value Disclosure	$ 0	$ 0

Note 2 - Fair Value Measureme_4

Note 2 - Fair Value Measurement - Financial Assets on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Inputs, Level 2 [Member]
Total Cash and cash equivalents	$ 0	$ 0
Fair Value, Measurements, Recurring [Member]
Total Cash and cash equivalents	30,657	6,663
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total Cash and cash equivalents	30,657	6,663
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total Cash and cash equivalents

Note 3 - Inventories - Summary

Note 3 - Inventories - Summary of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Raw materials	$ 1,453	$ 583
Work in progress	652	454
Finished goods	1,404	810
Total	$ 3,509	$ 1,847

Note 4 - Deferred Rent (Details

Note 4 - Deferred Rent (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Amortization of Deferred Rent	$ 127,000	$ 127,000
Increase (Decrease) in Deferred Liabilities, Total	$ (16,000)	$ (65,000)

Note 4 - Deferred Rent - Summar

Note 4 - Deferred Rent - Summary of Deferred Rent (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Landlord-funded leasehold improvements	$ 1,125	$ 1,125
Less accumulated amortization	(757)	(630)
Total (current portion $130 at December 31, 2018 and 2017)	368	495
Straight line rent adjustment	111	127
Total deferred rent	$ 479	$ 622

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		$ 5.4
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total	$ 2.3
Operating Loss Carryforwards, Reduction	$ 2.3

Note 5 - Income Taxes - Effecti

Note 5 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Federal tax expense (benefit) on net income/loss at statutory rate	$ 686	$ (855)
Change in valuation allowance	(412)	(3,419)
Basis difference related to investment in SAVSU		(110)
Return to provision	52	(1,038)
Federal rate change true-up		5,421
Stock compensation	(748)
Book loss in SAVSU	141
162(m) limitation on executive compensation deductibility	296
Other	(15)	1
Benefit (expense) for income taxes, net

Note 5 - Income Taxes - Deferre

Note 5 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets (liabilities)
Net operating loss carryforwards	$ 7,381	$ 8,162
Accrued compensation	181	32
Depreciation	(24)
Depreciation		43
Section 263a inventory adjustment	42	29
Stock-based compensation	664	688
Deferred rent	101
Outside basis difference in SAVSU
Outside basis difference in SAVSU		(225)
Other		28
Total	8,345	8,757
Less: Valuation allowance	(8,345)	(8,757)
Net deferred tax asset

Note 5 - Income Taxes - Operati

Note 5 - Income Taxes - Operating Loss Carryforwards (Details) $ in Thousands	Dec. 31, 2018USD ($)
Net Operating Losses	$ 35,147
Year 1 [Member]
Net Operating Losses	259
Year 2 [Member]
Net Operating Losses	2,849
Year 3 [Member]
Net Operating Losses	4,168
Year 4 [Member]
Net Operating Losses	1,217
Year 5 [Member]
Net Operating Losses	646
Year 6 [Member]
Net Operating Losses	589
Year 7 [Member]
Net Operating Losses	873
Year 8 [Member]
Net Operating Losses	2,607
Year 9 [Member]
Net Operating Losses	2,512
Year 10 [Member]
Net Operating Losses	2,196
Year 11 [Member]
Net Operating Losses	1,232
Year 12 [Member]
Net Operating Losses	1,028
Year 13 [Member]
Net Operating Losses	437
Year 14 [Member]
Net Operating Losses	37
Year 15 [Member]
Net Operating Losses	6,409
Year 16 [Member]
Net Operating Losses	3,093
Year 17 [Member]
Net Operating Losses	$ 4,995

Note 6 - Warrants - Summary of

Note 6 - Warrants - Summary of Warrant Activity (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Outstanding, Number (in shares)	6,689	7,603
Outstanding, Weighted average exercise price (in dollars per share)	$ 4.50	$ 4.46
Exercised, Number (in shares)	(2,609)	(914)
Exercised, Weighted average exercise price (in dollars per share)	$ 4.75	$ 4.18
Outstanding, Number (in shares)	4,080	6,689
Outstanding, Weighted average exercise price (in dollars per share)	$ 4.35	$ 4.50

Note 7 - Stock-based Compensa_3

Note 7 - Stock-based Compensation (Details Textual) - USD ($)	Feb. 27, 2018	Dec. 31, 2018	Dec. 31, 2017	May 31, 2017	Dec. 31, 2016	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance		279,919	237,926		98,439
Allocated Share-based Compensation Expense, Total		$ 1,519,000	$ 1,270,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		964,997	999,997		999,997
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		35,000
Restricted Stock [Member]
Allocated Share-based Compensation Expense, Total		$ 413,000	$ 149,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 1,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value		$ 1,300,000	365,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 1,100,000	$ 154,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		2,043,402	2,390,012		2,513,861
Allocated Share-based Compensation Expense, Total		$ 597,000	$ 612,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0	$ 1.91
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		330,983	131,427
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 3,800,000	$ 91,817
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		20,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 16,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		5 years 146 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 531,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 182 days
The 2013 Performance Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		2,600,000
The 2013 Performance Incentive Plan [Member] | Performance Shares [Member]
Common Stock, Capital Shares Reserved for Future Issuance				4,100,000		3,100,000
The 2013 Performance Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance		280,000
All Other Unapproved Compensation Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		425,000
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member]
Allocated Share-based Compensation Expense, Total		$ 509,000	$ 509,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		35,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		$ 285,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 4,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price			$ 1.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	999,997
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member] | Vesting on Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			50.00%
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member] | Vesting One Year After Release of Audited Financial Statements for 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			50.00%
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Management Performance Bonus Plan 2017 [Member] | Performance Shares [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%

Note 7 - Stock-based Compensa_4

Note 7 - Stock-based Compensation - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Granted (in shares)	0
Outstanding at end of year, weighted average exercise price (in dollars per share)	$ 1.91
Employee Stock Option [Member]
Outstanding at beginning of year (in shares)	2,390,012	2,513,861
Outstanding at beginning of year, weighted average exercise price (in dollars per share)	$ 1.85	$ 1.78
Granted (in shares)		155,000
Granted, weighted average exercise price (in dollars per share)		$ 2.93
Exercised (in shares)	(330,983)	(131,427)
Exercised, weighted average exercise price (in dollars per share)	$ 1.36	$ 1.17
Forfeited (in shares)	(15,627)	(52,932)
Forfeited, weighted average exercise price (in dollars per share)	$ 4.34	$ 3.45
Expired - vested (in shares)		(94,490)
Expired - vested (in dollars per share)		$ 1.78
Outstanding at end of year (in shares)	2,043,402	2,390,012
Outstanding at end of year, weighted average exercise price (in dollars per share)	$ 1.91	$ 1.85
Stock options exercisable at year end (in shares)	1,661,999	1,583,585
Stock options exercisable at year end, weighted average exercise price (in dollars per share)	$ 1.87	$ 1.72
Performance Shares [Member]
Outstanding at beginning of year (in shares)	999,997	999,997
Outstanding at beginning of year, weighted average exercise price (in dollars per share)	$ 1.64	$ 1.64
Granted (in shares)
Granted, weighted average exercise price (in dollars per share)
Exercised (in shares)	(35,000)
Exercised, weighted average exercise price (in dollars per share)	$ 1.64
Outstanding at end of year (in shares)	964,997	999,997
Outstanding at end of year, weighted average exercise price (in dollars per share)	$ 1.64	$ 1.64
Stock options exercisable at year end (in shares)	465,001
Stock options exercisable at year end, weighted average exercise price (in dollars per share)	$ 1.64

Note 7 - Stock-based Compensa_5

Note 7 - Stock-based Compensation - Shares Authorized Under Stock Option Plan (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Exercise price, upper range (in dollars per share)
Number of shares outstanding (in shares) | shares	2,043,402
Weighted average remaining contractual life (Year)	5 years 215 days
Weighted average exercise price (in dollars per share)	$ 1.91
Price Range 1 [Member]
Exercise price, lower range (in dollars per share)	0.49
Exercise price, upper range (in dollars per share)	$ 1
Number of shares outstanding (in shares) | shares	3,571
Weighted average remaining contractual life (Year)	2 years 332 days
Weighted average exercise price (in dollars per share)	$ 0.49
Price Range 2 [Member]
Exercise price, lower range (in dollars per share)	1.01
Exercise price, upper range (in dollars per share)	$ 1.50
Number of shares outstanding (in shares) | shares	412,073
Weighted average remaining contractual life (Year)	1 year 332 days
Weighted average exercise price (in dollars per share)	$ 1.24
Price Range 3 [Member]
Exercise price, lower range (in dollars per share)	1.51
Exercise price, upper range (in dollars per share)	$ 2.50
Number of shares outstanding (in shares) | shares	1,549,367
Weighted average remaining contractual life (Year)	6 years 189 days
Weighted average exercise price (in dollars per share)	$ 1.94
Price Range 4 [Member]
Exercise price, lower range (in dollars per share)	2.51
Exercise price, upper range (in dollars per share)	$ 8.60
Number of shares outstanding (in shares) | shares	78,391
Weighted average remaining contractual life (Year)	6 years 251 days
Weighted average exercise price (in dollars per share)	$ 4.99

Note 7 - Stock-based Compensa_6

Note 7 - Stock-based Compensation - Restricted Stock Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Non-vested at beginning of year (in shares)	237,926	98,439
Non-vested at beginning of year, grant date fair value (in dollars per share)	$ 1.79	$ 1.90
Unvested granted (in shares)	181,268	207,350
Granted, grant date fair value (in dollars per share)	$ 7.02	$ 1.76
Vested (in shares)	(116,647)	(51,563)
Vested, grant date fair value (in dollars per share)	$ 1.81	$ 1.90
Forfeited (in shares)	(22,628)	(16,300)
Forfeited, grant date fair value (in dollars per share)	$ 3.95	$ 1.76
Non-vested at end of year (in shares)	279,919	237,926
Non-vested at end of year, grant date fair value (in dollars per share)	$ 5	$ 1.79

Note 7 - Stock-based Compensa_7

Note 7 - Stock-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock compensation expense	$ 1,519	$ 1,270
Research and Development Expense [Member]
Stock compensation expense	260	237
Selling and Marketing Expense [Member]
Stock compensation expense	269	231
General and Administrative Expense [Member]
Stock compensation expense	809	638
Cost of Sales [Member]
Stock compensation expense	$ 181	$ 164

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)a	Dec. 31, 2017USD ($)
Operating Leases, Rent Expense, Net, Total	$ 809,000	$ 755,000
Bothell, Washington Headquarters [Member]
Area of Real Estate Property | a	32,000
Lessee, Operating Lease, Renewal Term	5 years
Monthly Base Rent Expense	$ 59,000

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 748
2020	764
2021	452
Total	$ 1,964

Note 9 - Preferred Stock (Detai

Note 9 - Preferred Stock (Details Textual) - USD ($)	Nov. 27, 2018	May 17, 2018	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Debt Conversion, Converted Instrument, Amount					$ 4,250,000
Preferred Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001
Stock Redeemed or Called During Period, Value				$ 4,250,000
Dividends Payable					$ 106,000
Series A Preferred Stock [Member]
Debt Conversion, Converted Instrument, Amount			$ 4,250,000
Debt Conversion, Converted Instrument, Shares Issued			4,250
Preferred Stock, Shares Outstanding, Ending Balance				0	4,250
Preferred Stock, Par or Stated Value Per Share					$ 1,000
Preferred Stock, Dividend Rate, Percentage					10.00%
Preferred Stock Redeemed or Called During Period, Percent		25.00%
Stock Redeemed or Called During Period, Shares	3,187	1,063
Stock Redeemed or Called During Period, Value	$ 3,187,000	$ 1,063,000
Dividends Payable				$ 0

Note 10 - Revenue - Disaggregat

Note 10 - Revenue - Disaggregated Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net product sales	$ 19,742	$ 11,022
Regenerative Medicine [Member]
Net product sales	11,029	5,307
Distribution Service [Member]
Net product sales	6,418	3,232
Drug Discovery [Member]
Net product sales	1,199	1,318
BioBanking [Member]
Net product sales	$ 1,096	$ 1,165

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Astero [Member]	Mar. 13, 2019USD ($)
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Combination, Consideration Transferred, Total	$ 12,500,000
Payments to Acquire Businesses, Gross	8,000,000
Business Combination, Consideration Transferred, Liabilities Incurred	4,500,000
Maximum Potential Earnout Payment for 2019, 2020, and 2021 [Member]
Business Combination, Contingent Consideration, Liability, Total	3,500,000
Maximum Potential Earnout Payment for 2021 [Member]
Business Combination, Contingent Consideration, Liability, Total	5,000,000
Indemnity Escrow Amount [Member]
Escrow Deposit	1,000,000
Indemnity Escrow, Payable to Sellers From the Initial Cash Payment and Closing [Member]
Escrow Deposit	250,000
Indemnity Escrow, Payable to Sellers From the Product Milestone Payment [Member]
Escrow Deposit	750,000
Product Milestone Escrow Amount [Member]
Escrow Deposit	$ 3,750,000